The Next Era of Health | Global Conference 2026

Systemic Challenges and Demographic Shifts

• Demographic Crisis: The U.S. is facing a tipping point where the population over 65 will soon outnumber those under 18.
• Economic Leverage: Adults over 50 contribute over $8.3 trillion in annual economic spending, necessitating targeted investment in aging infrastructure.
• Long-Term Care Gap: Most individuals over 65 require long-term care they cannot afford, with prices rising exponentially and the current system unprepared for demand.
• Caregiver Burden: 63 million caregivers provide care valued at $1 trillion annually, yet often lack training, recognition, or financial support.
• Health Span vs. Life Span: A 13-year gap exists between life expectancy and health expectancy; the U.S. prioritizes longevity over the duration of healthy living.

Innovation vs. Delivery Friction

• The "Downstream" Gap: Significant innovation exists in upstream discovery (genomics, risk identification), but the system fails to integrate these tools to prevent downstream acute events like heart attacks or fractures.
• Workforce Mismatch: Despite a surge in in-home health care jobs, the healthcare system lacks sufficient specialized professionals (e.g., genetic counselors) to support new technologies like widespread genetic profiling.
• Incentive Misalignment: The current fee-for-service model fails to reward prevention or quality outcomes; the U.S. is the only country where a top-tier surgeon receives the same reimbursement as a bottom-tier surgeon performing the same procedure.
• Transaction Costs: Administrative burden and transaction complexity account for 17–21% of healthcare spend (approx. $50–$80 billion annually), dwarfing the 10% spent on pharmaceuticals.
• Access Disparity: Over 50% of U.S. counties lack a cardiologist, creating a critical barrier to early detection and intervention for preventable diseases.

Global Competition and Biotech Race

• China's Acceleration: China has evolved from a low-cost manufacturer to a leader in innovation, accounting for nearly 50% of novel molecules licensed by Western pharma in the last year.
• Clinical Trial Velocity: Chinese clinical trials are running 2–5 times faster than U.S. trials at half the cost, causing capital flight and early-stage startups to migrate operations to China.
• Investment Shift: Venture capital and private equity are increasingly favoring China, with some U.S. VC firms shutting down domestic arms to invest exclusively in Chinese markets.
• Regulatory Goal: The target is to reduce the time from drug discovery to patient bedside from over 15 years to under 5 years through regulatory reform and in silico trials.

Technological Integration and AI

• AI Adoption Tiers: AI currently excels in "access" (agentic scheduling) and "efficiency" (ambient dictation, billing) but faces latency challenges in proving direct clinical "outcome" improvements.
• Agentic Solutions: The University of Miami Health System deployed an "agentic access agent" within eight weeks that outperformed human agents in scheduling, and a surgical AI agent covering the entire operating room lifecycle.
• Genomic Integration: A consortium (BioCog AI) is being formed to connect genomics, proteomics, and metabolomics data with electronic medical records to solve rare diseases.
• ARPA-H Initiatives: ARPA-H is investing $144 million in the first clinical trials for longevity, using biomarkers to measure aging in 3 years rather than waiting 30+ years for mortality endpoints.
• Future Clinical Tool: ARPA-H is partnering with FDA to develop the first FDA-authorized "agentic AI clinician" to expand cardiovascular prevention to counties without specialists.

Evidence Generation and Guideline Updates

• Speed of Evidence: The American Heart Association (AHA) and American College of Cardiology (ACC) are reducing guideline update cycles from 3–5 years to a target of 12–14 months.
• Process Constraints: Experts caution against instantaneous guideline updates, noting that clinical data requires "maturation" to identify long-term safety issues (e.g., gender representation in trials).
• Guideline Scope: AHA authors 20 joint guidelines, all stroke guidelines, all CPR guidelines (via ILCOR), and 100 annual scientific statements, adjudicated by committees reviewing thousands of comments.
• Prevention Investment: While 80% of cardiovascular disease is preventable, the system struggles to fund screening and early diagnosis; value-based models for prevention are still in experimental stages.

Forward-Looking Commitments (Next 12 Months)

• Heart Disease Therapy: Bob Bradway (Amgen) commits to demonstrating that reducing Lipoprotein(a) by 95% via new therapies leads to reduced heart attacks and strokes, challenging current 8-year guideline timelines.
• Women's Health Investment: The AHA will deploy capital from AHA Ventures to fund underappreciated solutions specifically for women's cardiovascular health.
• Caregiver Policy: AARP is prioritizing the advocacy of a federal caregiver tax credit to provide financial resources to the 63 million caregivers.
• Clinical Trial Reform: ARPA-H is launching a major push for technological and regulatory innovation in clinical trials, moving away from 60-year-old models.
• Genomic Consortia: The University of Miami will expand its BioCog AI consortium to connect multi-omics data with EMRs across multiple health systems.